Fatty liver disease refers to the accumulation of fat (triglycerides,) in the liver. The liver cell contains fats, but the accumulation of excess fat can be a cause of concern and can lead to liver inflammation known as steatohepatitis. The fatty liver can be caused by alcohol as well as can be non-alcohol. Steatohepatitis can cause liver cirrhosis (fibrosis, scarring, and hardening of the liver). The cause of non-alcoholic fatty liver disease (NAFLD) is unknown. The nonalcoholic fatty liver disease (NAFLD) is one of the most common diseases in the United States. The prevalence of nonalcoholic fatty liver disease (NAFLD) is rising due to rise in prevalence of diabetes and obesity. According to National Health and Nutrition Examination survey, about 20-30% of the general population in the western world suffer from nonalcoholic fatty liver disease (NAFLD). The common symptoms include fatigue, weakness, weight loss and others. The diagnosis of NAFLD requires the combination of different tests such as blood test, ultrasound, CT scan, MRI scan, and liver biopsy. The two types of Nonalcoholic fatty liver disease (NAFLD) includes simple fatty liver and Nonalcoholic Steatohepatitis (NASH). The simple fatty liver is a type of nonalcoholic fatty liver (NAFL), in which fat is deposited, but no inflammation or liver damage is observed. NASH is the inflammation of the liver due to excess fat deposit and can lead to liver damage and disease.
The global Non Alcoholic Fatty Liver Disease Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North America is estimated to lead the global nonalcoholic fatty liver disease treatment market due to increase in prevalence of diabetes and cardiovascular diseases in United States. Large number of manufacturers exist in the market, with large number of customer base. Asia Pacific market is also projected to experience high growth in the near future owing to factors such as, increase in healthcare expenditure, rising standard of living, lifestyle changes- attributed to better healthcare and awareness of the cost-effective treatment process with government grants and funding for acceleration in research and development activities.
This report aims to provide a comprehensive presentation of the global market for Non Alcoholic Fatty Liver Disease Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non Alcoholic Fatty Liver Disease Treatment.
Report Scope
The Non Alcoholic Fatty Liver Disease Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non Alcoholic Fatty Liver Disease Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non Alcoholic Fatty Liver Disease Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Pfizer
Roche
Daewoong
Cardax
Merck
Novartis
Gilead Sciences
AstraZeneca
Limerick BioPharma
GW Pharmaceuticals
Allergan
Takeda Pharmaceutical
Segment by Type
Antioxidants
Thiazolidinedione
Biguanides
Lipid lowering Agents
FXR Receptor Agonist
Others
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Drug Stores
Online Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non Alcoholic Fatty Liver Disease Treatment companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antioxidants
1.2.3 Thiazolidinedione
1.2.4 Biguanides
1.2.5 Lipid lowering Agents
1.2.6 FXR Receptor Agonist
1.2.7 Others
1.3 麻豆原创 by Application
1.3.1 Global Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Drug Stores
1.3.5 Online Pharmacy
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Perspective (2019-2030)
2.2 Non Alcoholic Fatty Liver Disease Treatment Growth Trends by Region
2.2.1 Global Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Non Alcoholic Fatty Liver Disease Treatment Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Non Alcoholic Fatty Liver Disease Treatment Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Dynamics
2.3.1 Non Alcoholic Fatty Liver Disease Treatment Industry Trends
2.3.2 Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Drivers
2.3.3 Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Challenges
2.3.4 Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non Alcoholic Fatty Liver Disease Treatment Players by Revenue
3.1.1 Global Top Non Alcoholic Fatty Liver Disease Treatment Players by Revenue (2019-2024)
3.1.2 Global Non Alcoholic Fatty Liver Disease Treatment Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non Alcoholic Fatty Liver Disease Treatment Revenue
3.4 Global Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Concentration Ratio
3.4.1 Global Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non Alcoholic Fatty Liver Disease Treatment Revenue in 2023
3.5 Non Alcoholic Fatty Liver Disease Treatment Key Players Head office and Area Served
3.6 Key Players Non Alcoholic Fatty Liver Disease Treatment Product Solution and Service
3.7 Date of Enter into Non Alcoholic Fatty Liver Disease Treatment 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Non Alcoholic Fatty Liver Disease Treatment Breakdown Data by Type
4.1 Global Non Alcoholic Fatty Liver Disease Treatment Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Non Alcoholic Fatty Liver Disease Treatment Forecasted 麻豆原创 Size by Type (2025-2030)
5 Non Alcoholic Fatty Liver Disease Treatment Breakdown Data by Application
5.1 Global Non Alcoholic Fatty Liver Disease Treatment Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Non Alcoholic Fatty Liver Disease Treatment Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Size (2019-2030)
6.2 North America Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Size by Country (2019-2024)
6.4 North America Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Size (2019-2030)
7.2 Europe Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Size by Country (2019-2024)
7.4 Europe Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Size (2019-2030)
9.2 Latin America Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Non Alcoholic Fatty Liver Disease Treatment Introduction
11.1.4 Pfizer Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Non Alcoholic Fatty Liver Disease Treatment Introduction
11.2.4 Roche Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2019-2024)
11.2.5 Roche Recent Development
11.3 Daewoong
11.3.1 Daewoong Company Detail
11.3.2 Daewoong Business Overview
11.3.3 Daewoong Non Alcoholic Fatty Liver Disease Treatment Introduction
11.3.4 Daewoong Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2019-2024)
11.3.5 Daewoong Recent Development
11.4 Cardax
11.4.1 Cardax Company Detail
11.4.2 Cardax Business Overview
11.4.3 Cardax Non Alcoholic Fatty Liver Disease Treatment Introduction
11.4.4 Cardax Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2019-2024)
11.4.5 Cardax Recent Development
11.5 Merck
11.5.1 Merck Company Detail
11.5.2 Merck Business Overview
11.5.3 Merck Non Alcoholic Fatty Liver Disease Treatment Introduction
11.5.4 Merck Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2019-2024)
11.5.5 Merck Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Non Alcoholic Fatty Liver Disease Treatment Introduction
11.6.4 Novartis Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2019-2024)
11.6.5 Novartis Recent Development
11.7 Gilead Sciences
11.7.1 Gilead Sciences Company Detail
11.7.2 Gilead Sciences Business Overview
11.7.3 Gilead Sciences Non Alcoholic Fatty Liver Disease Treatment Introduction
11.7.4 Gilead Sciences Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2019-2024)
11.7.5 Gilead Sciences Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Detail
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Non Alcoholic Fatty Liver Disease Treatment Introduction
11.8.4 AstraZeneca Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2019-2024)
11.8.5 AstraZeneca Recent Development
11.9 Limerick BioPharma
11.9.1 Limerick BioPharma Company Detail
11.9.2 Limerick BioPharma Business Overview
11.9.3 Limerick BioPharma Non Alcoholic Fatty Liver Disease Treatment Introduction
11.9.4 Limerick BioPharma Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2019-2024)
11.9.5 Limerick BioPharma Recent Development
11.10 GW Pharmaceuticals
11.10.1 GW Pharmaceuticals Company Detail
11.10.2 GW Pharmaceuticals Business Overview
11.10.3 GW Pharmaceuticals Non Alcoholic Fatty Liver Disease Treatment Introduction
11.10.4 GW Pharmaceuticals Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2019-2024)
11.10.5 GW Pharmaceuticals Recent Development
11.11 Allergan
11.11.1 Allergan Company Detail
11.11.2 Allergan Business Overview
11.11.3 Allergan Non Alcoholic Fatty Liver Disease Treatment Introduction
11.11.4 Allergan Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2019-2024)
11.11.5 Allergan Recent Development
11.12 Takeda Pharmaceutical
11.12.1 Takeda Pharmaceutical Company Detail
11.12.2 Takeda Pharmaceutical Business Overview
11.12.3 Takeda Pharmaceutical Non Alcoholic Fatty Liver Disease Treatment Introduction
11.12.4 Takeda Pharmaceutical Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2019-2024)
11.12.5 Takeda Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Pfizer
Roche
Daewoong
Cardax
Merck
Novartis
Gilead Sciences
AstraZeneca
Limerick BioPharma
GW Pharmaceuticals
Allergan
Takeda Pharmaceutical
听
听
*If Applicable.
